158 related articles for article (PubMed ID: 15752830)
1. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
[TBL] [Abstract][Full Text] [Related]
3. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
[TBL] [Abstract][Full Text] [Related]
4. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
[TBL] [Abstract][Full Text] [Related]
5. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
6. Immunization with virus-modified tumor cells.
Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
[TBL] [Abstract][Full Text] [Related]
7. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
Schirrmacher V; Haas C; Bonifer R; Ertel C
Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
[TBL] [Abstract][Full Text] [Related]
8. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
10. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
[TBL] [Abstract][Full Text] [Related]
11. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
12. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
13. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.
Termeer CC; Schirrmacher V; Bröcker EB; Becker JC
Cancer Gene Ther; 2000 Feb; 7(2):316-23. PubMed ID: 10770642
[TBL] [Abstract][Full Text] [Related]
14. Impaired interleukin-2 synthesis and T cell proliferation following antibody-mediated CD3 and CD2 or CD28 cross-linking in trans: evidence that T cell activation requires the engagement of costimulatory molecules within the immunological synapse.
Watson CL; Furlong SJ; Hoskin DW
Immunol Invest; 2008; 37(1):63-78. PubMed ID: 18214800
[TBL] [Abstract][Full Text] [Related]
15. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
Janke M; Peeters B; Zhao H; de Leeuw O; Moorman R; Arnold A; Ziouta Y; Fournier P; Schirrmacher V
Int J Oncol; 2008 Oct; 33(4):823-32. PubMed ID: 18813797
[TBL] [Abstract][Full Text] [Related]
16. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
[TBL] [Abstract][Full Text] [Related]
17. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.
Alvarez-Vallina L; Hawkins RE
Eur J Immunol; 1996 Oct; 26(10):2304-9. PubMed ID: 8898938
[TBL] [Abstract][Full Text] [Related]
19. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
20. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Int J Cancer; 2006 Feb; 118(3):658-67. PubMed ID: 16108015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]